Next-Generation Sequencing for Advanced Pancreatic Cancer: A Technology Whose Time Has NOT Come
Next-Generation Sequencing for Advanced Pancreatic Cancer: A Technology Whose Time Has NOT Come
About this item
Full title
Author / Creator
Publisher
Monmouth Junction: Intellisphere, LLC
Journal title
Language
English
Formats
Publication information
Publisher
Monmouth Junction: Intellisphere, LLC
Subjects
More information
Scope and Contents
Contents
[...]in the SWOG 1513 study (NCT02890355),2 E. Gabriela Chiorean, MD, and her colleagues showed, in a second-line chemotherapy setting, that perhaps 30% had some kind of DNA repair defective gene based on a defined ¡ §HDR¡ ¨ assay, yet the addition of a PARP inhibitor to FOLFIRI (folinic acid, 5-FU, oxaliplatin, and irinotecan) was not beneficial....
Alternative Titles
Full title
Next-Generation Sequencing for Advanced Pancreatic Cancer: A Technology Whose Time Has NOT Come
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2802941856
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2802941856
Other Identifiers
ISSN
0890-9091
